MDM2 amplification was most commonly seen among liposarcoma (63.6% [332 of 522]) followed by gallbladder, adenocarcinoma (11.1% [62 of 554]); sarcoma, not otherwise specified (10.7% [103 of 955]); and urothelial carcinoma (10.4% [198 of 1,898]; Table 1). Here, MDM2 is linked to sarcoma.